Opinion|Videos|May 5, 2025
Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
Advertisement
Episodes in this series
Panel Introduction
CROWN Trial and Lorlatinib Treatment in ALK+ Metastatic NSCLC
- Discussion focused on the 5-year data from the CROWN trial evaluating lorlatinib for ALK-positive metastatic NSCLC
- Analysis of how these long-term outcomes have influenced the current treatment paradigm
- Comparison of clinical trial results with real-world outcomes observed by treating physicians
Key Treatment Considerations
- Long-term survival benefits and durability of response with lorlatinib
- Emphasis on efficacy against brain metastases, which are common in ALK+ NSCLC
- Cost-effectiveness evaluations when selecting frontline treatment options
Clinical Implementation
- Real-world efficacy and safety profile of lorlatinib compared to clinical trial results
- Practical considerations in implementing treatments based on CROWN trial evidence
- Balance between efficacy outcomes and economic considerations in treatment decisions
Notable Insights
- Dr. Dietrich was asked to describe the CROWN trial design and elaborate on how the 5-year data has influenced the treatment landscape for ALK+ metastatic NSCLC, particularly regarding survival outcomes and response durability.
- Dr. Lovly addressed the unique long-term outcomes with lorlatinib, especially its efficacy against brain metastases, and discussed the complex balance between cost considerations and clinical efficacy when making frontline treatment decisions.
- Castronovo provided perspective on real-world clinical experience with lorlatinib, comparing observed efficacy and safety profiles with those reported in the controlled CROWN trial setting.
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5